Biomarkers are employed across the entire healthcare spectrum, from biological research laboratories to patient monitoring in clinics. Biomarker diagnostics and drug therapy combinations are providing the basis for the next generation of effective and beneficial treatments for a wide range of diseases.
The “2nd Berlin Conference on IP in Life Sciences” was aimed at addressing nearly every aspect of the development of diagnostics, focusing on the entire value chain, from research and development to marketing and reimbursement. Leading European life science experts from
business and research, biobanks, contract research and regulatory authorities were present at the conference, which was tailored specifically for biotech and pharma enterprises.
When:
February 13th, 2009, 9.00-17.00
Where:
Canadian Embassy, Leipziger Platz 17, 10117 Berlin, Germany
Tel +49 (0)30 20312-0 | www.berlin.gc.ca | (Map)
>>> Programm |
||||
9:00 | |
Welcome Address |
|
|
|
|
|
H.E. Dr. Peter Boehm, |
|
|
|
|
Dr. Hans-Rainer Jaenichen, |
||
| |
Key Note |
|||
|
Defining the diagnostic market and its potential |
Dr. Christian Peter, |
||
| |
Biomarker Discovery |
|||
|
Biobanking and Biomolecular Resources Research Infrastructure BBMRI |
Georges Dagher, |
||
| |
Biomarker Development |
|||
|
The R&D process in the pharmaceutical |
Dr. Simon Read, |
||
10:30 | |
Coffee Break |
|||
11:00 | |
Performance Evaluation |
|||
|
Accelerating Biomarker Assay Development to Validation |
Paul Smith, |
||
| |
Intellectual Property |
|||
|
Patenting nucleic acid-based biomarkers |
Dr. Christian Kilger, |
||
| |
Regulatory |
|||
|
The European approval pathway of diagnostic/drug combinations |
Jesus Rueda, |
||
12:30 | |
Lunch |
|||
13:30 | |
Intellectual Property |
|||
|
Patenting peptide-based biomarkers |
Dr. Ute Kilger, |
||
| |
Companion Diagnostics |
|
||
|
Diagnostic-based therapeutics in oncology |
Dr. Gabriele Beer, |
||
| |
Imaging |
|||
|
Combining in-vitro and imaging biomarkers for early detection of Alzheimer's Disease |
Dr. Lennart Thurfjell, |
||
15:00 | |
Coffee Break |
|||
15:30 | |
Reimbursement |
|||
|
Pricing strategies of IVD |
Dr. Jürgen Schulze, |
||
| |
Marketing |
|||
|
Marketing strategies of IVD |
Dr. Hartmut Goette, |
||
| |
Discussion/wrap up |
|||
|
Biomarkers and diagnostics: lessons learned |
|
|
|
17:00 | |
Networking |
|||
|
Cocktail Reception |
Invitation Canadian Embassy and Government of Ontario |
|
|
Contact and further information:
Uta Holmer
+49 (0)30 26 49 21-53
events@biocom.de